Farmson Analgesics

What Farmson Analgesics does

Farmson Basic Drugs Private Limited (operating as Farmson Analgesics) is a privately held, vertically integrated Indian manufacturer of Active Pharmaceutical Ingredients headquartered in Nandesari, Vadodara, Gujarat. Founded in 1969 by Late Mr. K.K. Vithani and now led by Chairman Dr. Apurva Patel and CEO Mr. Vinit Menon, the company is the global leader in Paracetamol API production, controlling approximately 22% of global supply and roughly 50% of India's domestic market across six manufacturing units with combined capacity of approximately 52,000–53,000 MTPA, equivalent to roughly 96.1 billion tablets per year. The company supplies pharmaceutical manufacturers in 65+ countries.

The product portfolio is centered on Paracetamol API manufactured via the PNCB (para-nitrochlorobenzene) route with in-house Hydrogenation, offered in multiple grades (fine powder, micro-fine, dense, crystalline, high-dense). It is forward-integrated into Directly Compressible (DC) Paracetamol granules (3,600 MTPA, GLATT fluid-bed technology, EU GMP certified), and backward-integrated into PAP (Para-Amino Phenol) via Hydrogenation (the only producer using this route) and Glacial Acetic Acid at 99.5% purity. Complementary offerings include a pharmaceutical-grade Caffeine API produced through a proprietary seven-stage synthesis (~300 MT/month, scalable to 600 MT/month) and a New APIs portfolio from Units 4 and 5 covering analgesics, CNS stimulants, and anti-diabetic molecules. The company holds a dense stack of regulatory certifications including WHO-GMP, EU GMP, EDQM, ANVISA, PMDA, Cofepris, MFDS, and NMPA, alongside Responsible Care (RC) Logo and Apex India Green Leaf Platinum recognition.

Farmson operates a sales-led B2B model with direct supply contracts to global pharmaceutical manufacturers; pricing is quote-based and not publicly disclosed. Distribution is direct, with no intermediaries, supported by industry events (notably CPHI Frankfurt 2025), content marketing via the corporate website and blog, and corporate social channels. Revenue streams include bulk Paracetamol API, DC Granules, Caffeine API, Glacial Acetic Acid byproduct, and the emerging New APIs portfolio.

Name

Farmson Analgesics

Legal name

Farmson Basic Drugs Private Limited

Website

https://farmson.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Farmson Basic Drugs is a privately held Indian manufacturer and global leader in Paracetamol API production, holding 22% global and 50% Indian market share. Six vertically integrated Gujarat plants supply pharmaceutical manufacturers across 65+ countries with bulk APIs, DC granules, and Caffeine.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Paracetamol API manufacturing
• Active pharmaceutical ingredients
• Pharmaceutical contract manufacturing
• Caffeine API production
• Directly compressible granules

Headquarters

HQ city

Vadodara

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. API Paracetamol Sales: Core revenue stream from manufacturing and selling Paracetamol Active Pharmaceutical Ingredient (API) to pharmaceutical companies worldwide. Products include various grades: fine powder, micro-fine powder, dense powder, crystalline, high-dense, and DC granules. Revenue generated through long-term supply contracts with pharmaceutical manufacturers.
2. Paracetamol DC Granules Sales: Forward integrated product - Directly Compressible Paracetamol granules for tablet manufacturers. Provides drum-to-feeder compression/encapsulation solutions that simplify manufacturing process for pharmaceutical customers.
3. Caffeine API Sales: Synthetic caffeine API production for pharmaceuticals, food, beverages, flavors, and fragrances industries. Seven-stage synthesis process produces pharmaceutical-grade caffeine (anhydrous) meeting IP, EP/BP, USP, JP standards.
4. Glacial Acetic Acid Sales: Byproduct of concentration process - Glacial Acetic Acid (99.5% purity) produced from dilute acetic acid, sold to other industries. Reduces transportation by 218,000 liters/day.
5. New APIs Portfolio: Expansion into new Active Pharmaceutical Ingredients from Units 4 & 5, diversifying product portfolio beyond Paracetamol. Targets high-demand molecules and integrated solutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Farmson manufactures and supplies Active Pharmaceutical Ingredients (APIs) primarily Paracetamol API at ~52,000 MTPA capacity via the PNCB route, along with Directly Compressible (DC) Paracetamol granules, pharmaceutical-grade Caffeine Anhydrous API, Glacial Acetic Acid, and an expanding portfolio of new APIs. The company serves pharmaceutical manufacturers in 65+ countries through direct B2B supply contracts, backed by multiple global regulatory certifications.

Product overview

Farmson Basic Drugs operates as a fully integrated pharmaceutical manufacturing company organized around six specialized manufacturing units in Gujarat, India. The core portfolio centers on Paracetamol API (manufactured via the PNCB route with in-house hydrogenation), which is available both as a standalone bulk Active Pharmaceutical Ingredient in multiple powder and crystalline grades and as a forward-integrated Directly Compressible (DC) granule product for tablet manufacturers. Complementary offerings include Caffeine API (produced via a seven-stage synthesis process) and Glacial Acetic Acid (produced at 99.5% purity for backward integration), alongside an expanding range of new APIs for analgesics, CNS stimulants, and anti-diabetic applications from Units 4 and 5. The company holds EU GMP, WHO-GMP, EDQM, ANVISA, and multiple other international certifications, positioning it as a vertically integrated, single-product-focused manufacturer with backward integration into key intermediates and forward integration into DC granules.

Differentiator

Problem solved

Functional benefit

Products and services

• Paracetamol API Active Pharmaceutical Ingredient (API) Paracetamol manufactured via the PNCB (para-nitrochlorobenzene) route with hydrogenation technology, available in multiple grades (fine powder, micro-fine powder, dense powder, crystalline, high-dense powder) compliant with BP, EP, IP, and USP pharmacopoeial standards. Supplied to global pharmaceutical manufacturers for finished dosage forms including tablets, capsules, syrups, suspensions, and effervescent tablets.
• Paracetamol DC (Directly Compressible) Granules Ready-to-use Directly Compressible Paracetamol granules for tablet manufacturing, enabling drum-to-feeder compression/encapsulation without a separate granulation step. Produced at EU GMP certified facility with 3,600 MTPA capacity using GLATT fluid-bed granulation technology. Available in grades of 97%, 96%, 90%, 84%, and 83.3% paracetamol content, compliant with EP, BP, USP, and IP pharmacopoeias.
• Caffeine API Pharmaceutical-grade Caffeine Anhydrous API manufactured through a proprietary seven-stage chemical conversion process producing approximately 300 metric tons per month (scalable to 600 MT/month). Meets IP, EP/BP, USP, and JP pharmacopoeial standards. Produced in stable Form-II polymorph with strict control over genotoxic and nitrosamine impurities. Used in pharmaceutical analgesic combinations, energy formulations, migraine medications, and food & beverage applications.
• Glacial Acetic Acid (GAA) Glacial Acetic Acid at 99.5% purity produced in-house for backward integration, reducing transportation by 218,000 liters per day and significantly cutting carbon emissions. Used as a key intermediate in Paracetamol API manufacturing, and also sold to other industries.
• New APIs Portfolio Expanding portfolio of new Active Pharmaceutical Ingredients manufactured at Units 4 and 5, including analgesics, CNS stimulants, and anti-diabetic drugs. Developed through the company's state-of-the-art R&D facility with multi-scale synthesis capabilities from grams to kilograms. Targets high-demand molecules and integrated solutions.

Quantifiable outcome

• 98.6% Bioavailability improvement with micro fine powder grade vs 60-minute dissolution time for standard grade
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Schneider ElectriccoreStrategic or Co-development Partner · 4 June 2025Farmson became a Green Yodha partner with Schneider Electric to champion ESG and decarbonization goals. This partnership focuses on advancing sustainability initiatives, implementing renewable energy solutions, and achieving environmental targets through collaborative efforts in green manufacturing practices.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• EUROAPI: European API manufacturer spun off from Sanofi in 2022, producing a wide range of small-molecule APIs. Comparable to Farmson in business model (B2B API manufacturer serving global pharma) and in regulatory-driven customer relationships.
• Divis Laboratories: Largest Indian API manufacturer by market cap, producing APIs and intermediates across multiple therapeutic categories. While not paracetamol-focused, it is a comparable Indian API exporter with similar regulatory-driven business model and global customer footprint.
• Ipca Laboratories: Indian pharmaceutical company producing APIs and formulations across multiple therapeutic areas. Comparable to Farmson in being an India-based API manufacturer with international regulatory approvals serving global pharma customers.
• Cambrex: US-headquartered CDMO and small-molecule API manufacturer owned by Permira. Comparable to Farmson as a B2B API manufacturer with global regulatory certifications serving major pharmaceutical customers, though serving a broader portfolio of molecules.
• Aurobindo Pharma: One of the largest Indian generic pharmaceutical manufacturers with substantial API operations. While diversified across many molecules, its API manufacturing scale and global export footprint make it a relevant broad incumbent comparable.

Direct peers

• Hunan Erkang Pharmaceutical: Major Chinese paracetamol and pharmaceutical intermediate producer. Competes head-to-head with Farmson in global paracetamol API markets, particularly in regulated geographies like Europe and North America.
• Granules India: Indian API and pharmaceutical intermediates manufacturer, listed on NSE/BSE. Comparable profile to Farmson as an Indian-headquartered API producer exporting globally, with overlapping customer base among generic pharma formulators.
• Shandong Xinhua Pharmaceutical: Major Chinese manufacturer of paracetamol API and other pharmaceutical chemicals. Listed in Hong Kong and one of the largest paracetamol producers globally, directly competing with Farmson's core product.
• Sri Krishna Pharmaceuticals: Hyderabad-based Indian paracetamol API manufacturer and a direct domestic/global competitor to Farmson. Focuses on paracetamol API and related intermediates serving similar pharmaceutical manufacturer customers.
• Anqiu Lu'an Pharmaceutical: One of China's largest paracetamol API manufacturers and a direct competitor to Farmson in the global paracetamol API market. Operates at large scale and is frequently cited as Farmson's primary Chinese rival in regulated markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Farmsonpharma/status/1807696622861840488
• YouTubeyoutube.com/watch?v=OHKxqIPwMqA
• LinkedInlinkedin.com/company/farmson-analgesics
• Instagraminstagram.com/farmsonbasicdrugs

Compliance16 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Farmson Analgesics